The Effects of Nebivolol on the NO-system in Patients With Essential Hypertension

• Status: Completed
• Trial end date: 2013-09-01
• Target enrollment: 0
• Participant gender: All

Summary

Investigators want investigate the following hypothesis:

1. Nebivolol increases nitric oxide activity in the systemic circulation and the kidney

2. The increased activity of nitric oxide during nebivolol treatment can be demonstrated by inhibition of NO synthesis with L-NMMA. We expect increased responses in blood pressure and sodium excretion is expected during nebivolol treatment compared to placebo.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Erling Bjerregaard Pedersen
• Treatments: Nebivolol

Criteria

Inclusion Criteria:

• Increased blood pressure (above 135 mmHg systolic or 85 mmHg diastolic in day time in 24 hour blood pressure measurement taking 5 or 10 mg amlodipine

• Men and women

• age 40 - 70 years

• informed consent

Exclusion Criteria:

• diabetes mellitus

• glomerular filtration rate < 30 ml/min

• albuminuria > 1,5 g/l

• renogram which suggests secondary hypertension

• clinical signs of pheochromocytoma or increased p-metanephrines

• clinical important sign og heart, lung, liver, thyroid or neoplastic diseases

• clinical important deviations in routine blood samples or ECG

• drug or alcohol abuse

• pregnancy or nursery

• intolerance to nebivolol

• blood donation with a month of the first examination day

• inacceptable increase in blood pressure durin L-NMMA infusion (200/120)

• inacceptable side effects to amlodipine

• blood pressure increase above 170/105 on highest dose amlodipine (10 mg)